In its September 2025 shareholder letter, CLINUVEL Chairman Professor Jeffrey V. Rosenfeld has painted a picture of a company that has not only delivered financial stability but also carved out a rare position as a profitable, dividend-paying biotech with no debt and a growing cash reserve. …
Latest Video
New Stories
-
The 'Dispatched' Week in Review - 12 September
September 12, 2025 - - Podcast -
Surely this is what the collapse of moral authority must look like
September 11, 2025 - - Latest News -
Artificial Intelligence can only accelerate Health Technology Assessments
September 11, 2025 - - Latest News -
Australian biotechs shine at Asia Pacific Cell and Gene Therapy Awards
September 11, 2025 - - Australian Biotech -
Trump administration announces new disclosure rules for medicine advertising
September 10, 2025 - - Latest News -
Chemist Warehouse partners with DoorDash to deliver health and beauty on demand
September 10, 2025 - - Latest News -
Cancer leaders unite to tackle equity and innovation at 2025 PCPA Summit
September 10, 2025 - - Latest News